^
Association details:
| Biomarker: | NF1 mutation |
|---|---|
| Cancer: | Glioma |
| Drug: | luvometinib (FCN-159) (MEK1 inhibitor, MEK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
499O - A phase II study to explore the efficacy and safety of FCN-159 in recurrent or progressive pediatric low-grade glioma (pLGG) with MAPK pathway-activated
Published date:
10/16/2023
Excerpt:
All pts were identified as BRAF or NF1 alterations (BRAF V600E 12/23, 52.2%, KIAA1549-BRAF fusion 8/23, 34.8% and NF1 mut 3/23, 13.0%). At a median follow-up of 7.79 months, 22 pts were evaluated for efficacy: 6 partial response (PR, 27.3%, unconfirmed PR 3), 9 minor response (MR, 40.9%, unconfirmed MR 2), and 7 stable disease (SD, 31.8%)...The preliminary study results showed that treatment of FCN-159 was remarkably efficacious for pLGG pts. FCN-159 is well tolerated and easily manageable, without new safety signal observed.
